OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis $515.00 -0.53 (-0.10%) As of 09:31 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFDA EventsFinancialsNews and TrendsSEC FilingsShort Interest About Genmab A/S Stock (OTCMKTS:GNMSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$515.00▼$515.0050-Day Range$329.25▼$580.0052-Week Range$232.34▼$581.00Volume500 shsAverage Volume2,783 shsMarket Capitalization$31.71 billionP/E Ratio43.64Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on treatments for cancer and other serious diseases. The company uses its antibody technologies, including DuoBody and HexaBody, to develop therapeutic candidates and works with pharmaceutical partners to advance and commercialize medicines. Products developed through Genmab programs include Darzalex, Tecvayli, Epkinly/Tepkinly and Rybrevant, which are marketed through partnerships. Genmab conducts research and development internationally, with operations in Europe, North America and Asia. The company is led by President and Chief Executive Officer Jan van de Winkel, who co-founded Genmab.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreGNMSF MarketRank™: 0.76153234358 of 5 starsGenmab A/S scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Genmab A/S. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 43.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 43.64, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.16.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.12% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 4.35.Change versus previous monthShort interest in Genmab A/S has recently decreased by 6.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.20 News SentimentGenmab A/S has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 1 article on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsGenmab A/S has minimal institutional ownership at this time.Read more about Genmab A/S's insider trading history. Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNMSF Stock News HeadlinesGenmab Files Articles of Association Dated November 10November 12, 2026 | tipranks.comGenmab Reports November 10 Executive Share SalesNovember 12, 2026 | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 17 at 1:00 AM | Porter & Company (Ad)Genmab Reports 22% Revenue Growth as Phase 3 Results Strengthen Oncology PortfolioNovember 5, 2026 | tipranks.comGenmab Gains After Phase 3 Ovarian Cancer Win for Rina-SOctober 23, 2026 | quiverquant.comQGenmab Grants Restricted Stock Units to Board After Extraordinary General MeetingOctober 7, 2026 | tipranks.comGMAB jumps as Genmab posts positive Phase 3 lymphoma dataOctober 5, 2026 | quiverquant.comQGenmab Discloses Darwin Global as 5.11% Major ShareholderOctober 2, 2026 | tipranks.comSee More Headlines GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed this year? Genmab A/S's stock was trading at $314.00 at the beginning of the year. Since then, GNMSF stock has increased by 64.0% and is now trading at $515.00. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Tuesday, February, 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by $2.55. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Genmab A/S had a net margin of 16.97% and a trailing twelve-month return on equity of 13.96%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include Genmab A/S (GMAB), Novo Nordisk A/S (NVO), Bavarian Nordic (BVNRY), GENMAB A/S/S (GMXAY), Micron Technology (MU), Alibaba Group (BABA) and Cigna Group (CI). Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:GNMSF CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees3,029Year Founded1999Profitability EPS (Trailing Twelve Months)$11.80 Trailing P/E Ratio43.64 Forward P/E RatioN/A P/E GrowthN/ANet Income$963 million Net Margins16.97% Pretax Margin21.93% Return on Equity13.96% Return on Assets6.47% Debt Debt-to-Equity Ratio0.81 Current Ratio2.46 Quick Ratio2.44 Sales & Book Value Annual Sales$3.72 billion Price / Sales8.52 Cash Flow$15.82 per share Price / Cash Flow32.56 Book Value$88.49 per share Price / Book5.82Miscellaneous Outstanding Shares61,570,000Free Float60,622,000Market Cap$31.71 billion OptionableNot Optionable Beta0.64 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:GNMSF) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.